Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

PURPOSE: No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has been associated with altered risk of breast cancer and variable promoter activity. Therefore, we evaluated the associ...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Schneider, Bryan P., Wang, Molin, Radovich, Milan, Sledge, George W., Badve, Sunil, Thor, Ann, Flockhart, David A., Hancock, Bradley, Davidson, Nancy, Gralow, Julie, Dickler, Maura, Perez, Edith A., Cobleigh, Melody, Shenkier, Tamara, Edgerton, Susan, Miller, Kathy D.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2008
Teme:
Breast Cancer
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2653128/
https://ncbi.nlm.nih.gov/pubmed/18824714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.16.1612
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki